PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy

Abstract

Increased expression and glycosylation of PD-L2 in tumors are an important mechanism for cetuximab therapy refractoriness. Thus, the combination of PD-L2 glycosylation inhibition and cetuximab is a potential therapeutic strategy for cancer.